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Genetic Predisposition to Prostate 
Cancer 
Abstract:  
Introduction: Prostate cancer (PrCa) is the commonest non-cutaneous cancer in men in the UK. 
Epidemiological evidence as well as twin studies point towards a genetic component contributing to 
aetiology.  
 
Sources of data: Key recently published literature.  
 
Areas of agreement: A family history of PrCa doubles the risk of disease development in first degree 
relatives. Linkage and genetic sequencing studies identified rare moderate-high risk gene loci which 
predispose to PrCa development when altered by mutation. Genome wide association studies have 
identified common single nucleotide polypmorphisms (SNPs) which confer a cumulative risk of PrCa 
development with increasing number of risk alleles. There are emerging data that castrate resistant 
disease is associated with mutations in DNA repair genes.  
 
Areas of controversy: Linkage studies investigating possible high risk loci leading to PrCa 
development identified possible loci on several chromosomes, but most have not been consistently 
replicated by subsequent studies. Germline SNPs related to PSA levels and to normal tissue 
radiosensitivity have also been identified though not all have been validated in subsequent studies.  
 
Growing points: Utilising germline SNP profiles as well as identifying high risk genetic variants could 
target screening to high risk groups, avoiding the drawbacks of PSA screening.  
 
Areas timely for developing research: Incorporating genetics into PrCa screening is being 
investigated currently using both common SNP profiles as well as higher risk rare variants. 
Knowledge of germline genetic defects will allow the development of targeted screening programs, 
preventive strategies and the personalised treatment of PrCa.  
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Introduction 
Prostate cancer (PrCa) is the commonest non-cutaneous cancer in men in the UK with a lifetime risk 
of 13.24%, making it the cancer with the highest life time risk in UK males1.  Although the mortality 
rate of PrCa has fallen since the 1990’s (by approximately 20%), the incidence has risen significantly 
in the last 25 years; this is mostly attributed to the advent of PSA testing. In 2012, 43,400 new cases 
of PrCa were diagnosed in the UK and 10,800 men died of the disease. Worldwide, there is a distinct 
geographical variation in the incidence of PrCa with the highest rates observed in the Caribbean,  
Australia and New Zealand and the lowest in South Central Asia 1 (Fig. 1).  
The aetiology of PrCa is not well understood, although epidemiological studies demonstrating a 
convergence of incidence rates in some populations migrating between areas with a low incidence 
to those with high incidence suggest environmental and lifestyle risk factors play a role;2 this trend 
has been reported for a number of Asian-American populations in the USA, for example, in Korean 
and Vietnamese men for whom the incidence of PrCa rose linearly between 1990 and 2008.3 This 
trend in incidence has not been observed in all populations migrating from Eastern countries to the 
West; in a study of migrants from the former Soviet Union to Germany, lower PrCa mortality and 
incidence were found in the migrants compared with the German rates with no increase in incidence 
in the longitudinal analysis4. This suggests a genetic effect on PrCa risk. Indeed, it has long been 
known that having a positive family history and/or a certain ethnic background such as Afro-
Caribbean, is a risk factor for PrCa development. Evidence from twin studies where monozygotic 
twins were compared with dizygotic twins5, as well as studies of familial PrCa highlight this. First 
degree relatives of PrCa patients have twice the risk of developing the disease compared to the 
general population6. In men diagnosed under the age of 60 years, the risk to their first degree 
relatives is more than fourfold that of those without a family history7. The variation in incidence 
according to ethnicity also suggests a genetic component to PrCa aetiology; rates are higher in 
African American men compared with Asian American men 8. This review will focus on hereditary 
(germline) genetic factors contributing to PrCa development, rather than somatic genetics. 
Germline genetics 
With the strong epidemiological evidence pointing to a hereditary component to the development 
of PrCa, much research into causative genes has been explored. Linkage studies investigating 
possible high risk loci leading to PrCa development identified possible loci on several chromosomes, 
but most have not been consistently replicated by subsequent studies9  with the exception of 
HOXB13 (see later). Linkage studies investigate the co-segregation of genetic markers with a disease. 
The lack of significant findings from these studies suggests that the hereditary aetiology of PrCa has 
a significant polygenic inheritance.  
With the advances in genomic technology and high throughput DNA sequencing techniques, and by 
utilising databases of millions of common (mean allele frequency >5%) single nucleotide 
polymorphisms (SNPs) such as the HapMap 10 and 1000 Genomes project 11, genome wide 
association studies (GWAS) have been developed to investigate the (common) genetic variants 
predisposing to cancer. GWAS allows investigators to take an unbiased approach when scanning the 
genomes of thousands of cases and controls to identify SNPs that associate with cancer12. GWASs 
have enabled the discovery of SNPs in or near genes previously not known to be involved in cancer 
development. From projects, such as the HapMap project, it is known that certain SNPs will tend to 
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occur together although they are located separately, and not always within the same gene10. This 
phenomenon known as linkage disequilibrium (LD) allows a GWAS to utilise several hundred 
thousand ‘tag SNPs’ to generate data on millions of SNPs. One of the first published GWASs was 
carried out in PrCa cases 13 and since then several GWASs have been carried out yielding about 100 
PrCa risk SNPs, accounting for 33% of the familial relative risk in European ancestry populations (See 
list of SNPs in supplementary table online) 14. Several GWASs have been carried out in non-European 
populations such as Korean, Japanese, Arab and West African men to reveal both shared risk SNPs as 
well as some SNPs that may be unique to these populations (all GWASs are listed in the National 
Human Genome Research Institute and European Bioinformatics Institute (NHGRI-EBI) Catalog of 
published GWASs: http://www.ebi.ac.uk/gwas). 
PrCa risk SNPs identified in most GWAS analyses confer a low to moderate risk of disease 
development with odds ratios (OR) ranging from 0.74-1.62. 9 Therefore, single risk SNPs do not pose 
a clinically significant effect on their own, but the risk is cumulative (multiplicative or log additive) 
and increases with increasing numbers of risk alleles present in an individual. GWASs utilising 
catalogues of commonly occurring SNPs are not powered to detect rarer (MAF <1%) occurring 
variants which may have a higher relative risk of PrCa development.  GWASs specifically investigating 
rarer variants may reveal these higher risk single nucleotide variants (SNV), but these studies will 
require very large populations to detect risk SNVs. With the formation of international consortia 
such as PRACTICAL (PRostate Cancer Association group To Investigate Cancer Associated Alterations 
in the genome), these types of GWAS will become more feasible. Some high risk SNVs are already 
known such as those residing in the HOXB13 gene and were discovered by sequencing genes in 
regions of chromosome 17 identified by linkage studies of familial PrCa cases. The HOXB13 G84E 
mutation was found to confer an OR of 5.1. 15 
Another rare variant conferring an increased relative risk of PrCa is mutation of the BRCA2 gene. This 
was reported by the Breast Cancer Linkage Consortium (BCLC) which found that the BRCA2 mutation 
conferred approximately a five-fold relative risk in PrCa development, which increases to a risk of 
more than sevenfold in families with young onset cases (<65 years)16. This association has been 
confirmed by several research groups worldwide and there is evidence that the BRCA2 mutation is 
associated with more aggressive disease as well as earlier age of onset17. Germline variants in other 
DNA repair genes have also been implicated in PrCa development and will be discussed later.   
Germline SNPs associated with prostate cancer 
As well as SNPs associated with the development of PrCa, SNPs associated with outcome of 
treatment and radiotherapy toxicity have been identified. These germline genetic variants may 
prove to be useful clinically as the technology to identify them becomes more accessible within 
healthcare systems.  
Over 100 SNPs associated with the development of PrCa have been identified thus far. The most 
recently identified variants that contributed to these data were found through a large meta-analysis 
by Al-Olama et al of >10 million SNPs from GWASs in populations of European, African, Japanese and 
Latino ancestry. By combining data from trans-ethnic GWASs, 23 new risk SNPs were identified, 7 of 
which were detected from the multi-ancestry analyses. As with most GWASs in oncology, the initial 
and largest studies have focused on European populations with limited availability of data from 
ethnic minority populations. By combining data across populations, study sample and study power is 
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increased. This approach also provides an independent replication sample set which can overcome 
concerns of subpopulation stratification effects in single population GWASs, and it enables the 
identification of rare variants by fine-mapping the association signals that persist across genetically 
diverse populations 18.  
Of the latest 23 SNPs, one was found to be associated with early onset disease in men of European 
ancestry with an OR of 1.18 (rs636291 at 1p36; risk allele frequency= 0.16; P=2.1x10-8) 14. As with 
previous GWASs in PrCa, identified risk variants did not distinguish between aggressive and non-
aggressive disease.  
Although initial GWASs have focussed on European populations, recent studies in non-European 
cohorts have revealed population specific differences in the frequency of certain risk loci. This may 
partially explain the geographical and population differences in PrCa rates. For example, in the study 
of a Chinese population carried out via the PRACTICAL consortium using the iCOGS SNP array, 4 loci 
on 8q24 were found to contribute considerably to PrCa risk in a large proportion of men. Although, 
the SNPs didn’t reach GWAS level of significance, the frequency of these loci are much higher than 
that reported in European men, highlighting population specific differences in PrCa risk. 19 
Interestingly, differences in somatic genetic changes have also been noted between European and 
Chinese men, for example a much lower frequency in Chinese men was observed of the 21q22.2-
22.3 deletion affecting the ERG-TMPRSS2  fusion gene and 10q23 deletion, both of which are 
common in European PrCas; whether these differences are related to environmental or germline 
genetic factors is not known. 20    
Many of the PrCa risk SNPs identified in this study and previous GWASs are located in intronic non-
coding regions of DNA. Therefore, the mechanism contributing to PrCa development is not clearly 
defined and functional characterisation of these genetic variants is needed to understand this 
further. Several mechanisms have been proposed to explain how these SNPs may contribute to 
cancer risk, for example, the identified SNP may in fact be in LD with the causative SNP and act as a 
proxy for a variant in a coding exon which is not detected by GWAS. Alternatively, a SNP may cause a 
structural change in the promoter binding site of a gene and in turn affect its expression21. For 
example, the PrCa risk SNP, rs10993994, which is located 2 bp upstream of the transcription start 
site of the MSMB gene, is thought to affect several predicted transcription factor binding sites. 22 
MSMB encodes PSP94 (prostatic secretory protein of 94 amino acids) which is secreted by prostate 
tissue and is found at lower levels in prostate tumour tissue compared to healthy prostates. 23 It may 
be more specific as a diagnostic tool than PSA.24 The region surrounding this SNP has been shown to 
be critical for MSMB promoter activation25 and functional studies have demonstrated that mutations 
at rs10993994 directly affect expression of PSP9426 and this may play a role in PrCa development 
through interactions with other genes such as NCOA4 which lies adjacent to MSMB.25  
A SNP may also cause a change in the expression of long non-coding RNAs (lncRNA). These are 
evolutionally conserved and biologically functional non-coding RNA transcripts. The mechanism by 
which they interact with phenotype-causing loci is unclear although studies suggest that they can 
regulate the expression of genes lying in close proximity or target distant transcriptional activators 
or repressors27. A complete list of PrCa associated SNPs are included in the review by Eeles et al. 9 
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Clinical applications of GWAS data 
Screening using PSA related SNPs 
The most obvious use of GWAS data discussed so far would be in the context of screening, early 
diagnosis and ideally prevention of PrCa development. Germline DNA is an attractive entity for use 
in PrCa screening, as it acts as a constant risk factor which is easily accessible and requires a single 
measurement rather than serial measurements. Currently, PSA measurement with or without digital 
rectal examination (DRE) is used as a screening method in men who present with symptoms or 
concerns related to PrCa development. Screening questions often include enquiries related to a 
family history of PrCa. Studies assessing the use of these methods and particularly serum PSA 
measurement in large scale screening programs have suggested that the impact of overdiagnosis 
and over-treatment of indolent disease outweighs the benefit of detection of PrCa. 28 As a result, 
both the UK National Screening Committee (UK NSC) 29 and the U.S. Preventive Services Task Force 
(USPSTF) have made recommendations against PSA-based population screening. The UK NSC 
recommendation is currently under review but likely to remain unchanged despite recent evidence 
suggesting that screening may improve overall survival and metastasis free survival. 30, 31 PSA levels 
are prone to fluctuation and are affected by benign conditions such as prostatic hypertrophy as well 
as infection (both systemic and localised) and inflammation. Conversely, PrCa may be diagnosed in 
the presence of a ‘normal’ PSA level and therefore there is a risk of false negatives in the use of PSA 
screening.  
Indeed, 40%-45% of the variation in PSA levels is accounted for by hereditary factors and GWAS have 
identified SNPs that associate with PSA level exclusively rather than PSA level and PrCa risk. 
Gudmundsson et al carried out a GWAS investigating SNPs correlating with PSA levels in men 
without PrCa 32. Six SNPs were identified, 3 of which were not previously known. Although the 3 loci 
previously described had been shown to associate with PrCa as well as PSA levels, two of the newly 
identified SNPs (at 10q26 and 12q24) were found to associate exclusively with PSA levels, while the 
third (at 5p13) exerted only a moderate risk on PrCa development. The investigators propose using 
this knowledge of genetic variant association with PSA level to apply a ‘genetic correction’ to 
commonly used PSA thresholds. This will in turn produce a personalised PSA cutoff value to decide if 
a man should undergo a prostate biopsy. In their study population of Icelandic and UK men, this 
approach improved the accuracy of prediction of biopsy outcome.  This improvement was greater 
when the ‘genetic correction’ of PSA level was combined with the effect of PrCa risk SNPs also 
present. 32 As knowledge of genetic variant associations develops, personalised PSA thresholds may 
become a feasible tool that could be incorporated into PrCa screening. It must be noted though that 
GWAS data and subsequent risk SNPs identified can only be applied to populations similar to that 
used in the original studies unless validation studies in other ethnic groups are carried out.  
Differences in SNP profiles between different ethnic groups exist and therefore, GWASs in other 
populations are needed; some have already been carried out such as in the Korean study by Kim et 
al which identified PSA related SNPs different to those observed in the Icelandic/UK GWAS. 33 
A UK study assessing the use of PSA related SNPs in improving the discrimination achieved by a 
single PSA threshold in men with raised PSA levels 34 found that genetically correcting PSA levels in 
men with a level between 3-10 ng/mL did not improve the differentiation between high and low risk 
PrCa. This suggests that current knowledge of SNPs affecting PrCa risk and prostate related variables 
may be most useful when used in conjunction with other biomarkers such as PrCa risk SNPs (as done 
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in the study by Gudmundsson et al) or clinical factors such as in the STHLM3 model (described 
below) and cannot be solely relied upon clinically.  
Screening using prostate cancer risk SNPs 
Screening models incorporating PrCa associated SNPs have been suggested. Using the currently 
known PrCa risk SNPs, men who are in the top 1% of the risk distribution are thought to have a 
relative risk of 4.7 fold compared with the average risk of the general reference population. Risk 
modelling suggests that the cumulative effect of risk SNPs could be used in large scale programs to 
target screening to high risk groups. 14  
A retrospective study using a cohort from the screened arm of the American Prostate, Lung, 
Colorectal and Ovary (PLCO) study showed that profiling germline PrCa SNPs (33 SNPs producing a 
prostate genetic score (PGS)) can identify men who have a higher risk of developing disease, with 
men in the top quartile of PGS-33 score having the highest risk detection rate of PrCa.35 
 In a recent prospective Swedish study, a screening model (STHLM3) combining plasma protein 
biomarkers (PSA, free PSA, intact PSA, hK2, MSMB and MIC1), 232 risk SNPs and a set of defined 
clinical variables (age, family history, previous prostate biopsy and prostate examination) were 
compared with PSA measurement alone (using a threshold of ≥3ng/ml). 36 The STHLM3 model 
performed significantly better than PSA measurement for the detection of Gleason 7 or higher PrCa. 
The investigators concluded that using the STHLM3 model would reduce the number of prostate 
biopsies by one third, the number of benign biopsies by 44% and the number of Gleason 6 PrCas 
biopsied by 17%. Gleason 6 PrCas are usually categorised as low risk and many don’t require 
treatment. If the results using this screening model can be replicated and validated in other 
populations, this would partially address the overdiagnosis of indolent cancers observed in PSA 
screening studies as well as the risk of prostate biopsies to men without cancer, but further 
refinement of this model is needed as there was still a significant number of low grade cases 
diagnosed; over half of the tumours were Gleason 6 cancers. Sensitivity for the detection of high risk 
PrCas was significantly improved with the STHLM3 model; the AUC with PSA alone was 0.56 
compared with 0.74 with the study model. Notably, 21% of the high risk PrCas diagnosed by the 
STHLM3 model had a PSA level in the range of 1-3 ng/ml and would not have been detected by PSA 
screening alone. It is unclear whether all the components of the STHLM3 algorithm would be needed 
in a large scale screening program, although all the variables used were significantly associated with 
high risk PrCa and contributed to a cumulative improvement in the AUC in the multivariate analysis. 
This was the first large prospective and population based PrCa screening study assessing a targeted 
approach to screening. As modifications of this strategy continue to be investigated, for example 
with the use of other biomarkers such as the four-kallikrein panel (included in STHLM3) and the 
incorporation of MRI and targeted biopsies (currently under investigation), it is likely that a practical 
and more feasible model for population screening will arise in the future.  Further prospective 
studies are needed to assess how PrCa risk SNPs can be used to target screening to men at increased 
risk of developing cancer.  As further PrCa risk SNPs are identified in future studies, effectively 
utilising these clinically, will require independent evaluation and validation of their association with 
PrCa development. 
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Germline SNPs as predictive and prognostic biomarkers 
In the work up of newly diagnosed PrCa, management options are decided depending on factors 
such as T staging, Gleason score on pathology and presenting PSA level. Patients are assigned a risk 
category of low, intermediate or high. Although treatment is often straightforward for patients with 
high risk disease (e.g. Gleason score >7 or T4 stage), for low and intermediate risk cases, 
management can include active surveillance (AS). Many patients seek to delay interventional 
treatment due to the risk of long term side effects. In patients who are managed with AS, 
approximately 33% will progress to definitive treatment by 5 years.37 Being able to prognosticate 
and predict outcome based on a profile of germline SNPs would enable a personalised approach to 
treatment and allow identification of men for whom interventional treatment should be applied.  
Predicting aggressive disease 
Kearns et al studied a cohort of White American men (n=950) with Gleason 6 PrCa who underwent a 
radical prostatectomy (RP) and assessed their germline DNA for a set of 23 SNPs to investigate a 
correlation with upgrading of Gleason score.38  Three SNPs, rs11568818 on chromosome 11, 
rs2427345 on chromosome 20 and rs7141529 on chromosome 14, were found to be significant 
predictors of upgrading Gleason score. These SNPs can be biologically linked to PrCa development; 
rs11568818 on chromosome 11 lies within an exon of MMP7 (matrix metalloproteinase 7) which 
may have a role in PrCa invasiveness.  rs2427345 on chromosome 10 lies in an intron associated with 
GATA5 and CABLES2, which are involved in cell cycle progression, and rs7141529 on chromosome 14 
lies in an intron upstream of RAD51B, which is a component of the DNA mismatch repair pathway.39 
The SNPs, rs11568818 (OR=1.46, P=0.0009), and rs2427345 (OR=1.32, P=0.02) remained significant 
predictors of upgrading Gleason score in a univariate logistic regression model. As well as these 
SNPs, age and serum PSA level were associated with upgrading disease, which suggests that genetic 
variant information could be combined with other clinical factors to assess risk category and allow 
more robust risk stratification. The 3 SNPs were also evaluated in an independent AS cohort 
analysing time to event. Although this cohort was much smaller, the HR (ranged from 3.7-5.3) for 
upgrading Gleason score was statistically significant for all 3 SNPs.  
An earlier GWAS including only PrCa cases identified two loci that associated with Gleason score: 
rs35148638 at 5q14.3 and rs78943174 at 3q26.31.40 A subsequent case-control analysis showed that 
the 5q14.3 SNP is specific for aggressive PrCa (P=8.85x10-5) and doesn’t associate with non-
aggressive disease compared to controls (P=0.57). Although both SNPs are intronic, they lie within 
genes that may have a biological role in PrCa development.  The 5q14.3 SNP lies within RASA1 which 
acts a RAS suppressor and is involved in vascular development as well as cellular proliferation and 
differentiation. The 3q26.31 SNP lies within the NAALADL2 gene which is a member of the glutamate 
carboxypeptidase II family that also includes prostate-specific  membrane antigen (PSMA/ 
NAALADL1). NAALADL2 is overexpressed in prostate tumours and a higher level of expression in 
tumours has been associated with higher Gleason scores and poorer prognosis after radical 
prostatectomy. Further studies are needed to  assess the use of SNP panels in disease 
prognostication and PrCa management.  
Predicting radiation toxicity 
Radiotherapy is the mainstay of curative treatment in a large proportion of PrCa cases. The 
improvement in techniques of radiation dose delivery and minimisation of the volume of normal 
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tissues irradiated has led to improved outcomes in acute and late toxicity rates. Despite this, some 
patients will be significantly troubled by radiation side effects and late effects may only be seen from 
2 years after the end of treatment. GWASs in the area of radiogenomics have identified SNPs that 
appear to predict a predisposition to radiotherapy side effects.41-45 Predictive markers of late 
radiotherapy toxicity such as urinary and erectile dysfunction would enable treatment to be 
personalised to reduce toxicity or permit dose escalation based on one’s genetic profile of normal 
tissue sensitivity.46 As cure rates and life expectancy continue to increase with improved treatments 
and earlier diagnosis, maintaining quality of life for patients treated curatively is an important 
priority.  
Early genetic studies targeting candidate genes that may be involved in radiotherapy toxicity showed 
conflicting results. 47With the advancement of the field of radiogenomics and utilising the GWAS 
approach, patterns of genetic variant association with specific toxicities are becoming apparent. 
Table 1 summarises identified SNPs related to radiotherapy toxicity in the PrCa setting identified by 
GWAS. Other genetic variants have been identified in candidate gene studies related to radiotherapy 
toxicities in breast and oesophageal cancer treatment46.  
Explorative successful GWASs require large patient numbers to establish significant association 
findings, as well as validation in subsequent replication cohorts. This is becoming more feasible with 
the formation of large consortiums such as the Radiogenomics Consortium and the EU funded 
REQUITE project (Validating predictive models and biomarkers of radiotherapy toxicity to reduce 
side effects and improve quality of life in cancer survivors). Once robust predictive genetic profiles 
are established in the field of radiogenomics, a true personalised approach to radiotherapy planning 
can be taken. As with the PrCa screening models previously discussed, the ideal way of utilising 
radiosensitivity SNPs is likely to involve incorporating them into normal tissue complication 
probability models (NTCP) along with other patient specific factors such as age, gender and race, to 
optimise radiotherapy delivery individually and minimise acute and long term toxicity.48  (Fig. 2)  
Rare genetic variants 
The PrCa associated SNPs discussed so far confer a low to moderate risk of disease but do contribute 
cumulatively to a man’s risk of PrCa development. The GWAS approach is based on the common 
disease common variant hypothesis and most are powered to detect SNPs with allele frequencies of 
≥5%. To detect rare variants (MAF <1-5%) which may confer a higher risk of disease, larger 
populations of cases and controls are needed and even then very rare SNVs may be missed. 
HOXB13 
The HOXB13 G84E germline mutation was identified in four PrCa families after sequencing 200 genes 
on 17q21 and 17q22 (these regions were previously identified by linkage studies) 15. This mutation 
confers an OR of 5.1 for the development of PrCa and is more common in men with early onset 
disease (3.1%) compared with late onset (0.6%). A subsequent study showed that 5% of PrCa 
families carried this variant and were mostly of European descent49, with the highest proportion 
(22.4%) observed in PrCa families from Finland and Sweden (8.2%). Two missense mutations of 
HOXB13 were also detected, one in an African American family and the other in an African-
Caribbean family. HOXB genes encode transcription factors of the homeobox family, but the 
mechanism by which mutation leads to prostate carcinogenesis is unknown. Mouse studies have 
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shown that the HOXB13 protein is involved in prostate development50  and has been linked to the 
growth of PrCa cell lines in an androgen-independent manner51.  
BRCA1 and 2 
Mutations of the BRCA2 tumour suppressor gene have also been shown to increase the risk of PrCa 
development. A fivefold increased risk was reported by the BCLC 16. BRCA1 mutations also appear to 
increase the risk of PrCa development although this is less pronounced than with BRCA2 mutations; 
the BCLC reported a 1.8-fold increased risk up to the age of 65 years with BRCA1 mutation. This 
association was confirmed by Leongamornlert et al who found the frequency of BRCA1 mutation in a 
cohort of 900 PrCa cases to be 0.45%, conferring a relative risk of 3.75 fold and an 8.6% cumulative 
risk by the age of 65 years. 52  
BRCA1 and 2 are involved in the homologous recombination (HR) DNA repair pathway. In the field of 
hereditary breast and ovarian cancer, BRCA mutation associated disease is known to be responsive 
to PARP inhibitors (PARPi), in keeping with the concept of synthetic lethality, as well as platinum 
based chemotherapy. These response patterns have led to the investigation of PARPi in the PrCa 
setting. In the recently published phase II TOPARP study 53, PrCa patients treated with the PARPi 
Olaparib were assessed for both germline and somatic mutations in DNA repair genes. Of the 49 
patient cohort, 16 were found to have homozygous deletions, deleterious mutations or both in DNA 
repair genes. Of these, 6 had a germline mutation (3 in BRCA2 and 3 in ATM). In the 16 patients with 
DNA repair gene mutations, 14 (88%) had a response to treatment including in all 3 germline BRCA2 
mutation carriers. Although the numbers of patients in this study are small, the clinical implications 
of these results are significant, both in the somatic and germline genetic settings. With the 
advancing progress of personalised medicine and molecularly targeted agents in oncology in the last 
3 decades, identifying high risk genetic variants in the hereditary PrCa setting would extend this 
personalised approach further to allow targeted screening and surveillance of higher risk individuals 
thereby leading to earlier diagnosis and earlier access to curative treatment. Olaparib has recently 
been approved by the FDA and EMA for the treatment of platinum sensitive BRCA-mutated 
(germline and/or somatic) high grade serous epithelial ovarian cancer. If the responses to olaparib 
seen in TOPARP-A are replicated in the expansion cohort currently being enrolled into TOPARP-B 
(patients selected based on predictive DNA repair gene mutations in tumour tissue), it is highly likely 
that olaparib will be become an option for PrCa treatment in the near future.  
The IMPACT study is addressing the area of PrCa screening (using biopsy in those with a PSA >3 
ng/ml) in BRCA1 and BRCA2 carriers as well as men with Lynch Syndrome. Initial results from the first 
screening round in this study which involved BRCA1 and BRCA2 carriers and controls have shown a 
higher positive predictive value for PSA triggered biopsy in BRCA2 carriers (PPV 48%) compared with 
controls (PPV 33%).54 PrCa detected in BRCA2 carriers was classified as intermediate or high risk in 
two thirds of cases. Similarly, in the BRCA1 carriers, 61% were found to have intermediate or high 
risk disease. 54  
The findings of higher risk disease in BRCA mutation carriers may lead to worse outcomes as 
reported in a retrospective study by Castro et al 17, further emphasizing the argument for screening 
such high risk individuals. In this study of 67 BRCA mutation carriers and 1235 non-carriers, both 
metastasis free survival and cause specific survival were significantly lower in the BRCA mutation 
carriers. (Fig. 3) 
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Other DNA repair genes in prostate cancer 
Previous to the TOPARP study revealing PrCa patients with germline mutations in ATM as well as 
BRCA2, there have been reports of PrCa associations with other DNA repair gene mutations. In a 
sample of 191 PrCa patients with ≥3 cases of PrCa in their family, 7.3% were found to harbour a 
germline loss of function (LoF) mutation in a tumour suppressor gene55. These genes included BRCA 
1 and 2, ATM, mismatch repair (MMR) genes (MLH1, MLH3, MSH2, MSH6) and RAD51C among 
others (Fig. 4), and all belonged to one of four DNA damage response pathways. Similar to the 
correlation of BRCA2 mutation with advanced disease, this retrospective study also showed that LoF 
mutation carriers have an increased risk of having advanced disease (defined by nodal or distant 
metastases or T4 disease) with an odds ratio of 15.09.55  
Recently published data by Pritchard et al has reported an even higher frequency of germline 
mutations in a larger unselected group of PrCa.56 In a cohort of 692 men with metastatic castration 
resistant PrCa, 11.8% (82 men) were found to carry a germline mutation in a DNA repair gene. Again, 
the highest rates were found in the BRCA2 and ATM genes. The finding of higher than expected rates 
of germline mutations in men with advanced PrCa may lead to the use of genetic screening in the 
oncology setting after diagnosis with metastatic PrCa, similar to the recent initiation of BRCA1/2 
mutation screening for all women diagnosed with  high grade serous ovarian cancer regardless of 
age or family history. 57    
Increasing our understanding of the germline genetic variants predisposing to PrCa will also 
complement the understanding of somatic mutations and prostate carcinogenesis. This is already 
happening in the ovarian cancer arena, where 50% of epithelial ovarian cancers (EOCs) display 
defects of the HR DNA repair pathway (termed HRD) which appear to confer sensitivity to PARPi as 
well as platinum chemotherapy, but only about 15% are accounted for by germline BRCA mutations. 
The remainder are thought to be caused by a range of genetic and epigenetic alterations of HR genes 
which has led to the investigation of candidate biomarkers of HRD to predict response to PARPi in 
non-BRCA mutated EOC. 58 
Similarly, as the evidence for the increased risk of PrCa in patients with germline mutations 
accumulates, clinical trials are also investigating somatic mutations that may predict response to 
targeted agents. After the presentation of the results of the TOPARP-A study, the TOPARP-B study is 
now enrolling PrCa patients whose tumour DNA harbours a mutation in a DNA repair gene. Only 
patients with a deleterious mutation will receive Olaparib. Similarly, a study of a PI3K inhibitor and 
enzalutamide in PrCa is selecting patients whose tumours are PTEN deficient (NCT02215096, 
www.clinicaltrials.gov).  
Future of prostate cancer genetics 
The rapid advances in genomic technology, along with the falling costs of genetic sequencing and the 
collaboration between large uro-oncology networks has led to an accumulation of data that we have 
yet to fully understand. For example, many of the PrCa risk SNPs conferring a low or moderate risk 
lie in non-coding regions of DNA and further studies are needed to identify how these SNPs interact 
with coding regions or whether in fact some SNPs are actually in linkage with a causative SNP 
elsewhere in the genome. Functional studies of causative SNPs are needed to understand how they 
promote prostate carcinogenesis. Studies of gene-environment interactions, under the umbrella of 
11 
 
the Collaborative Oncological Gene-Environment Study (COGS), are also underway to assess how 
germline SNPs interact with lifestyle factors to impact on the risk of PrCa development.  
Even without complete functional information related to how SNPs cause PrCa, utilising known risk 
SNPs to target PrCa screening is being explored. Whether these SNP profiles can be used 
independent of other factors such as family history, age and PSA level is unclear but with future risk 
modelling studies, the ideal way of utilising one’s genetic profile will become more apparent. By 
targeting PrCa screening to high risk groups, both in terms of common SNPs and rare genetic 
variants such as BRCA 1 and BRCA 2, the adverse effects of population screening such as biopsy 
complications and over treatment of low risk disease may be avoided. If the risk of aggressive 
disease can also be predicted from one’s genetic profile, then treatment of early stage disease that 
is not clearly aggressive may also be justified.  
Although the focus of the current discussion has surrounded the germline genetics of PrCa 
development, the role of somatic genetics is evolving rapidly with the advent of personalised 
treatments targeted to tumour specific molecular defects. The most recent demonstration of this 
was seen in the TOPARP study where somatic mutations of DNA repair genes were targeted clinically 
with the PARP inhibitor, Olaparib.  
With the efforts in developing personalised approaches to cancer management at the forefront of 
oncology research priorities, utilising germline genetic profiles to predict risk of disease 
development as well as other factors such as disease aggressiveness and treatment toxicity, 
combined with molecular target identification from somatic tumour profiles, will allow the 
development of a truly tailored approach to the screening for and treatment of PrCa.  
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Figure 1: Top 20 countries worldwide with the highest age standardised rate (ASR) of prostate 
cancer per 100,000 population.  
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Figure 2: Knowledge of an individual’s genetic profile can: A. Identify men at high risk of prostate 
cancer development and be incorporated into a targeted screening program. B. Allow the 
personalisation of treatment for example by modifying radiation dose or offering targeted agents 
such as PARP inhibitors.  
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Figure 3: Kaplan-Meier survival curves for BRCA 1/2 mutation carriers (orange) and controls (black); 
A. Metastasis free survival B. Cause specific survival.  
Reprinted from European Urology, 68, Castro et al, Effect of BRCA Mutations on Metastatic Relapse and Cause-
specific Survival After Radical Treatment for Localised Prostate Cancer, 186-93, Copyright (2015), with 
permission from Elsevier 
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Figure 4: Proportion of loss of function mutations by gene in 14 of 191 cases of familial prostate 
cancer 
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Table 1: Common prostate cancer risk SNPs identified through GWAS and other studies 
Locus SNP Effect 
allele  
Major 
Allele  
Per allele OR* Nearby genes  Reference  
3p12 rs2660753 C T 1.13 (1.08-1.19)   45 
6q25  rs9364554 C T 1.10 (1.06-1.14) SLC22A3 45 
7q21  rs6465657 T C 1.10 (1.07-1.13) LMTK2 45 
10q11  rs10993994 C T 1.24 (1.20-1.28) MSMB 45 
11q13 rs7931342 G G 1.20 (1.16-1.23)   45 
19q13  rs2735839 G G 1.23 (1.18-1.30) KLK2/3 45 
Xp11  rs5945619 T C 1.28 (1.21-1.35) NUDT11 45 
2p21  rs1465618 C T 1.07 (1.04-1.11) THADA 45 
2q31  rs12621278 A A 1.33 (1.25-1.43) ITGA6 45 
4q22  rs17021918 C C 1.14 (1.10-1.18) PDLIM5 45 
4q22  rs12500426 C A 1.10 (1.06-1.13) PDLIM5 45 
4q24  rs7679673 C C 1.15 (1.11-1.18) TET2 45 
8p21  rs2928679 G A 1.04 (1.01-1.07) SLC25A37 45 
8p21  rs1512268 C T 1.13 (1.10-1.17) NKX3.1 45 
11p15 rs7127900 G A 1.23 (1.18-1.28)   45 
22q13 rs5759167 G G 1.19 (1.15-1.22)   45 
8q24    rs10086908 T T 1.15 (1.06-1.23)   46 
8q24 rs12543663 A C 1.08 (1.00-1.16)   46 
8q24   rs620861 
 
C C 1.11 (1.04-1.19)   46 
19q13  rs11672691 G A 1.08 (1.05-1.12) PCAT19 47, 48 
2p11 rs10187424 T T 1.09 (1.06-1.12)   49 
2q37  rs7584330 A G 1.06 (1.02-1.09) MLPH 49, 50 
3q23  rs6763931 G A 1.04 (1.01-1.07) ZBTB38 49 
3q26 rs10936632 A A 1.11 (1.08-1.14)   49 
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5p12  rs2121875 A C 1.05 (1.02-1.08) FGF10 49 
5p15  rs2242652 C C 1.15 (1.11-1.19) TERT 49, 51 
5p15  rs2853676 C T 1.09 (1.05-1.12) TERT 51 
5p15  rs2736107 C T 1.12 (1.08-1.15) TERT 51 
5p15  rs13190087 A C 1.20 (1.12-1.29) TERT 51 
6p21  rs130067 T G 1.05 (1.02-1.09) CCHCR1 49 
12q13 rs10875943 T C 1.07 (1.04-1.10)   49 
Xq12  rs5919432 T C 1.06 (1.02-1.12) AR 49 
1q21 rs1218582 A G 1.06 (1.03-1.09)   52 
1q32 rs4245739 A A 1.10 (1.05-1.14)   52 
2p25 rs11902236 C T 1.07 (1.03-1.10)   52 
2q37  rs3771570 C T 1.12 (1.08-1.17) FARP2 52 
3q13 rs7611694 A A 1.10 (1.08-1.14)   52 
4q13 rs1894292 G G 1.10 (1.06-1.12)   52 
5q35 rs6869841 C T 1.07 (1.04-1.11)   52 
6p21  rs3096702 G A 1.07 (1.04-1.10) NOTCH4 52 
6q21 rs2273669 A G 1.07 (1.03-1.11)   52 
6q25 rs1933488 A A 1.12 (1.09-1.15)   52 
7p15  rs12155172 G A 1.11 (1.07-1.15) SP8 52 
8p21  rs11135910 C T 1.11 (1.07-1.16) EBF2 52 
10q24  rs3850699 A A 1.10 (1.06-1.12) TRIM8 52 
11q22  rs11568818 T T 1.10 (1.06-1.14) MMP7 52 
12q24  rs1270884 G A 1.07 (1.04-1.10) TBX5 52 
14q22  rs8008270 C C 1.12 (1.08-1.16) FERMT2 52 
14q24  rs7141529 T C 1.09 (1.06-1.12) RAD51B 52 
17p13 rs684232 T C 1.10 (1.07-1.14)   52 
17q21 rs11650494 G A 1.15 (1.09-1.22)   52 
18q23 rs7241993 C C 1.09 (1.05-1.12)   52 
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20q13 rs2427345 C C 1.06 (1.03-1.10)   52 
20q13  rs6062509 T T 1.12 (1.09-1.16) ZGPAT 52 
Xp22 rs2405942 A A 1.14 (1.09-1.20)   52 
1q21  rs17599629 A G 1.10 (1.07-1.13) GOLPH3L 13 
2p25  rs9287719 T C 1.07 (1.04-1.09) NOL10 13 
4q13 rs10009409 C T 1.09 (1.06-1.12)   13 
6p21  rs3129859 G G 1.08 (1.06-1.11) HLA-DRA 13 
6p22  rs7767188 G A 1.08 (1.06-1.11) TRIM31 13 
6p24  rs4713266 C C 1.08 (1.04-1.09) NEDD9 13 
7p12  rs56232506 G A 1.07 (1.05-1.09) TNS3 13 
9p21  rs17694493 C G 1.10 (1.06-1.13) CDKN2B-AS1 13 
10q11  rs76934034 T T 1.14 (1.10-1.18) Mar-08 13 
11q23  rs11214775 G G 1.08 (1.05-1.11) HTR3B 13 
12q13 rs80130819 A A 1.12 (1.08-1.18)   13 
14q24 rs8014671 G G 1.08 (1.05-1.10)   13 
Xp11  rs2807031 T C 1.07 (1.04-1.09) XAGE3 13 
Xq13 rs6625711 T A 1.07 (1.05-1.08)   13 
Xq13 rs4844289 A G 1.05 (1.04-1.07)   13 
1q32  rs1775148 T C 1.06 (1.03-1.08) SLC41A1 13 
6q14  rs9443189 A G 1.07 (1.04-1.11) MYO6 13 
14q23  rs7153648 G C 1.09 (1.04-1.13) SIX1 13 
16q22  rs12051443 G A 1.06 (1.03-1.08) PHLPP2 13 
20q13  rs12480328 T T 1.14 (1.08-1.18) ADNP 13 
21q22  rs1041449 A G 1.06 (1.04-1.09) TMPRSS2 13 
22q11  rs2238776 G G 1.09 (1.06-1.12) TBX1 13 
1p35  rs636291 G A 1.18(1.12-1.24) PEX14 13 
2p15 rs721048 G A 1.12 (1.07-1.16)   13 
3q21  rs10934853 C A 1.12 (1.08-1.16) EEFSEC 13 
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7p15  rs10486567 G G 1.18 (1.12-1.22) JAZF1 55 
8q24 rs1447295 C A 1.42 (1.35-1.49)   56 
8q24 rs6983267 G G 1.22 (1.19-1.27)   57 
8q24 rs16901979 C A 1.55 (1.43-1.68)   12 
9q33  rs1571801 G T 1.27 (1.10-1.48) DAB2IP 58 
10q26  rs4962416 T C 1.04 (1.00-1.09) CTBP2 55 
12q13  rs902774 G A 1.17 (1.11-1.24) KRT8 50 
17q12  rs4430796 A A 1.22 (1.19-1.27) HNF1B 59 
17q12  rs11649743 G G 1.14 (1.10-1.19) HNF1B 60 
17q24 rs1859962 T G 1.19 (1.14-1.23)   59, 61 
19q13 rs8102476 C C 1.12 (1.08-1.15)   54 
22q13  rs9623117 T C 1.11 (1.04-1.19) TNRC6B 62 
2p24  rs13385191 G G 1.15 (1.10-1.21) C2orf43 63 
3p11 rs2055109 T C 1.20 (1.13-1.29)   64 
5p15  rs12653946 C T 1.26 (1.20-1.33) IRX4 63 
6p21  rs1983891 C T 1.15 (1.09-1.21) FOXP4 63 
6q22  rs339331 T T 1.22 (1.15-1.28) RFX6 63 
9q31  rs817826 T C 1.41 (1.29-1.54) RAD23B 65 
10q26 rs2252004 C C 1.16 (1.10-1.22)   64 
17q21  rs7210100 G A 1.51 (1.35-1.69) ZNF652 66 
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Table 2: SNPs associated with radiation toxicity 
Locus- Nearest 
Gene(s) 
SNP Toxicity 
endpoint 
OR (95% CI) Proposed mechanistic 
relationship 
Ref 
2q24.1 - TANC1 rs264663 Overall toxicity, 
late toxicity 
6.6 (2.2-19.6) TANC1 involved in repair 
of muscle damage 
33 
9p21.2 - IFNK and 
MOB3B 
rs17779457 
(one of 8 SNPs 
in a haplotype 
block) 
Urinary 
symptoms e.g. 
incomplete 
emptying, 
intermittency, 
frequency 
No OR 
published. 
Beta 
coefficient 
2.4 
IFNK a member of type 1 
IFN family with a role in 
inflammatory response 
to radiation induced 
tissue damage. 
MOB3B essential for 
mitotic checkpoint 
regulation. 
31 
11q14.3 - SLC36A4 rs7120482 
rs17630638 
Rectal bleeding 3.1 (1.7-5.6) 
2.9 (1.6-5.2 
SLC36A4 encodes amino 
acid transporter needed 
for cellular proliferation.  
67 
10q26.3 - GLRX3 
19q13.43 - NLRP11 
 
rs11017104 
rs7245988 
 
(two of 12 SNPs 
discovered in 
this GWAS) 
Erectile 
dysfunction 
1.5 (0.7-3.0) 
2.0 (0.9-4.4) 
12 SNPs identified that lie 
near genes involved in 
biological activities of 
erectile function. 
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